Research and the next chapter
Established medicines help fund long research cycles, production capacity and selected scientific acquisitions.
HomeThe work behind
OUR WORK
The work behind
our medicines.
Scientific work, dependable production and commercial relationships connect across Asteria.
Explore the FY2025 portfolio
HOW WORK CONNECTS
Follow the work,
not just the name.
US commercial channels
US commercial channels include hospital networks and specialty-care providers, wholesalers and pharmacy networks, specialty pharmacies, and government/public-health procurement.
Singapore’s connected capabilities
Singapore combines biologics manufacturing, process research and Asia distribution.
OUR FY2025 PORTFOLIO
Different areas.
Different scientific questions.
Asteria’s 2025 portfolio spans oncology, immunology, vaccines and specialty medicines, alongside research tools, alliances and intellectual-property licensing.
Full-year 2025 overview. Portfolio classifications do not indicate approval, availability or development stage.
Inside the portfolio
The names. The products.
Explore the product names featured in the Asteria company film, then open their portfolio entries below.
Stills from the Asteria company film. Fictional product imagery; no clinical indication or regulatory status is implied.
11 portfolio entries · FY2025
Veylora
AreaOncologyPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Veylora is classified in Asteria’s Oncology area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Neralis
AreaOncologyPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Neralis is classified in Asteria’s Oncology area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Velmune
AreaImmunologyPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Velmune is classified in Asteria’s Immunology area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
AsterShield
AreaVaccinesPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
AsterShield is classified in Asteria’s Vaccines area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Seasonal respiratory portfolio
AreaVaccinesPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Seasonal respiratory portfolio is classified in Asteria’s Vaccines area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Cardiava
AreaSpecialtyPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Cardiava is classified in Asteria’s Specialty area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Neuromax
AreaSpecialtyPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Neuromax is classified in Asteria’s Specialty area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Research consumables and tools
AreaTools and otherPortfolio typeProduct portfolioFY2025 PORTFOLIO PROFILE
Research consumables and tools is classified in Asteria’s Tools and other area as part of the product portfolio.
Business context
Product revenue was $5.00 billion in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Partner development alliance
AreaOncologyPortfolio typeAlliance portfolioFY2025 PORTFOLIO PROFILE
Partner development alliance is classified in Asteria’s Oncology area as part of the alliance portfolio.
Business context
Collaboration and alliance revenue was $980 million in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Regional commercialization alliances
AreaSpecialtyPortfolio typeAlliance portfolioFY2025 PORTFOLIO PROFILE
Regional commercialization alliances is classified in Asteria’s Specialty area as part of the alliance portfolio.
Business context
Collaboration and alliance revenue was $980 million in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
Platform and process licenses
AreaIP licensingPortfolio typeLicensing and royalty portfolioFY2025 PORTFOLIO PROFILE
Platform and process licenses is classified in Asteria’s IP licensing area as part of the licensing and royalty portfolio.
Business context
Royalty and license revenue was $200 million in FY2025. This is a group-wide revenue category, not revenue attributed to this individual entry.
This company reference does not specify this entry’s approval, availability, development stage or clinical indications.
No matching portfolio entries.
Try a different name or area, or reset the filters to see all 11 entries.